BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36243829)

  • 21. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
    Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
    J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 23. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.
    Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F
    Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
    Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study.
    Ludwig DR; Romberg EK; Fraum TJ; Rohe E; Fowler KJ; Khanna G
    Pediatr Radiol; 2019 May; 49(6):746-758. PubMed ID: 31069473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of US LI-RADS in the LI-RADS Algorithm.
    Rodgers SK; Fetzer DT; Gabriel H; Seow JH; Choi HH; Maturen KE; Wasnik AP; Morgan TA; Dahiya N; O'Boyle MK; Kono Y; Sirlin CB; Kamaya A
    Radiographics; 2019; 39(3):690-708. PubMed ID: 31059393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound.
    Tse JR; Shen L; Bird KN; Yoon L; Kamaya A
    AJR Am J Roentgenol; 2022 Nov; 219(5):774-783. PubMed ID: 35703411
    [No Abstract]   [Full Text] [Related]  

  • 29. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
    Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
    AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
    [No Abstract]   [Full Text] [Related]  

  • 30. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma.
    Cunha GM; Hasenstab KA; Delgado T; Ichikawa S; Lee MH; Dautt Medina PM; Kim SJ; Lee YH; Kwon H; Sirlin CB; Fowler KJ
    Eur Radiol; 2021 Oct; 31(10):7594-7604. PubMed ID: 33876298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
    Yang D; Hu H; Li R; Tang CL; Ma KS; Guo DY
    Abdom Radiol (NY); 2022 Feb; 47(2):630-639. PubMed ID: 34910237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and clinical significance of discordant LI-RADS
    Yokoo T; Singal AG; Diaz de Leon A; Ananthakrishnan L; Fetzer DT; Pedrosa I; Khatri G
    Abdom Radiol (NY); 2020 Jan; 45(1):177-187. PubMed ID: 31342103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.
    Ehman EC; Behr SC; Umetsu SE; Fidelman N; Yeh BM; Ferrell LD; Hope TA
    Abdom Radiol (NY); 2016 May; 41(5):963-9. PubMed ID: 27193793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abbreviated MRI with second shot arterial phase for HCC evaluation: modified version of LI-RADS and recall reduction strategy.
    Kim JW; Lee CH; Kim KA; Lee J; Park YS
    Eur Radiol; 2023 Jun; 33(6):4401-4411. PubMed ID: 36562784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follow Up Imaging in Hepatocellular Cancer Ultrasound Screening Exams With Poor Visualization Scores.
    Bley E; Mohan N; Jackson I; Chaisidhivej N; Jarrett S; Lo KB; Navarro V; Rossi S; Rodgers SK; Kalman RS
    J Ultrasound Med; 2022 Dec; 41(12):3113-3118. PubMed ID: 36063062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 39. Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria.
    Rimola J; Sapena V; Brancatelli G; Darnell A; Forzenigo L; Mähringer-Kunz A; Paisant A; Renzulli M; Schima W; Terraz S; Valls C; Wagner M; Ayuso C; Vilgrain V; Reig M; Ronot M
    Hepatology; 2022 Nov; 76(5):1318-1328. PubMed ID: 35349760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.